Discovery of Novel Antitumor Small-Molecule Agent with Dual Action of CDK2/p-RB and MDM2/p53

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Cell cycle-dependent kinase 2 (CDK2) regulates cell cycle progression into S-phase.
• MDM2 is a key regulator of p53 and is implicated in tumor progression.
• Targeting CDK2 and MDM2 represents a potential therapeutic strategy for cancer.

Purpose of the Study:

• To identify and characterize a novel dual inhibitor of CDK2 and MDM2.
• To evaluate the antitumor activity of the identified compound in vitro and in vivo.
• To assess the druggability of the lead compound for potential therapeutic applications.

Main Methods:

• In vitro enzyme assays to determine CDK2 inhibitory activity and selectivity.
• Cell proliferation assays using various tumor cell lines.
• In vivo tumor xenograft models in mice.
• Pharmacokinetic and bioavailability assessments.

Main Results:

• A dual inhibitor, III-13, selectively inhibited CDK2 activity and reduced MDM2 expression.
• III-13 demonstrated potent inhibition of tumor cell proliferation across diverse cell lines, irrespective of CCNE1 status.
• In vivo studies confirmed significant tumor growth inhibition without adverse effects on body weight.
• Druggability assessment revealed low oral bioavailability and poor membrane permeability, indicating a need for further optimization.

Conclusions:

• III-13 is a promising lead compound for developing novel antitumor agents.
• The compound shows efficacy against CCNE1-amplified tumors.
• Further structural modifications are necessary to improve the pharmacokinetic properties of III-13 for oral administration.